Research Radar

New PubMed studies on repurposed drugs and natural compounds in cancer — summarized in plain language and reviewed by a person before posting.

How to read this page. These studies are automatically collected from PubMed and summarized by AI from the abstract, then reviewed by a human before publishing. Each summary describes only what that study reported — most are early lab, animal, or small human studies, and findings often conflict. This is educational information, not medical advice, and not a recommendation to take anything. Always talk with your oncologist.

Topic tags. Each study is filed under its main topic. Anticancer studies are the default; these tags flag the other dimensions:

Safety — Safety & interactionsAbsorption (PK) — How it's absorbed (PK)Formulation — Formulation & deliverySupportive care — Symptom & supportive careMetabolism — Metabolism & pathwaysTrial — Clinical trialMechanism — Biomarker & mechanism

Showing studies that mention “colon cancer”.

Human onlyPositive outcomesSafety signalsTrials2 of 72 studies

ReviewMechanismMixed resultsLimited evidenceTier 1 · lab

Nucleobindin-2/Nesfatin-1-A New Cancer Related Molecule?

International journal of molecular sciences · Aug 2021 · review

breast cancercolon cancerprostate cancerendometrial cancerthyroid cancerbladder cancerglioblastomaadrenocortical carcinomaovarian epithelial carcinoma

This review discusses nucleobindin-2/nesfatin-1 (NUCB2/NESF-1) as a cancer-related molecule. It summarizes reports that higher expression is linked with poorer outcomes and with increased cancer cell proliferation, migration, and invasion in several cancers, while other reports suggest it may inhibit growth in some cancer cell types. The article does not present new experimental data.

Key findings

High NUCB2/NESF-1 expression has been associated with poor outcomes in several cancers.
Reported effects include increased cell proliferation, migration, and invasion in breast, colon, prostate, endometrial, thyroid, and bladder cancers, and glioblastoma.
The review also notes conflicting findings where nesfatin-1 inhibited proliferation in human adrenocortical carcinoma and ovarian epithelial carcinoma cells.
The authors propose NUCB2/NESF-1 as a prognostic and predictive marker in cancers.

Limitations: Review article; no original experimental or clinical data.; The abstract summarizes heterogeneous prior studies with conflicting findings.; No quantitative effect estimates are reported in the abstract.; No details on study quality, sample sizes, or methods of the cited studies are provided..

This is a review of a molecule reported to be associated with cancer progression and prognosis, not a primary intervention study.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewMechanismReported positiveLimited evidenceTier 4 · clinical

The role of CT10 regulation of kinase-like in cancer

Future oncology (London, England) · Dec 2014 · Review

gastric cancerglioblastoma multiformehepatocellular carcinomabladder cancerlung cancercolon cancerovarian cancerleukemiabreast cancerhead and neck cancerrhabdomyosarcomaneuroblastoma

This is a narrative review summarizing published reports about the adaptor protein CRKL in cancer. The authors report that CRKL is overexpressed in many tumor types and appears to promote aggressive or malignant behaviors, and they suggest CRKL has potential as a diagnostic/prognostic biomarker.

Key findings

CRKL is a member of the CRK family and functions as an adaptor protein in intracellular signal transduction.
CRKL has been reported overexpressed in a variety of cancers.
CRKL appears to play a tumor-promotion role in multiple cancers, including those listed in the abstract.
The review summarizes associations between CRKL and malignant tumor behaviors and potential mechanisms of action.
The authors state CRKL has potential to be used as a biomarker for diagnosis, treatment and prognosis of certain tumors.

Limitations: This is a review article and does not present new primary experimental data.; Abstract provides no information on search strategy, inclusion criteria, or quality assessment of included studies.; Heterogeneity across many cancer types and study designs likely limits generalizability of conclusions.; The abstract does not report quantitative synthesis or effect sizes..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed